Association Between Metformin Therapy and Mortality After Breast Cancer

Author:

Lega Iliana C.1,Austin Peter C.23,Gruneir Andrea123,Goodwin Pamela J.24,Rochon Paula A.123,Lipscombe Lorraine L.123

Affiliation:

1. Women’s College Research Institute, Women’s College Hospital, Toronto, Ontario, Canada

2. Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada

3. The Institute for Evaluative and Clinical Sciences, Toronto, Ontario, Canada

4. Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.

Abstract

OBJECTIVE Metformin has been associated with a reduction in breast cancer risk and may improve survival after cancer through direct and indirect tumor-suppressing mechanisms. The purpose of this study was to evaluate the effect of metformin therapy on survival in women with breast cancer using methods that accounted for the duration of treatment with glucose-lowering therapies. RESEARCH DESIGN AND METHODS This population-based study, using Ontario health care databases, recruited women aged 66 years or older diagnosed with diabetes and breast cancer between 1 April 1997 and 31 March 2008. Using Cox regression analyses, we explored the association between cumulative duration of past metformin use and all-cause and breast cancer–specific mortality. We modeled cumulative duration of past metformin use as a time-varying exposure. RESULTS Of 2,361 breast cancer patients identified, mean (± SD) age at cancer diagnosis was 77.4 ± 6.3 years, and mean follow-up was 4.5 ± 3.0 years. There were 1,101 deaths(46.6%), among which 386 (16.3%) were breast cancer–specific deaths. No significant association was found between cumulative duration of past metformin use and all-cause mortality (adjusted hazard ratio 0.97 [95% CI 0.92–1.02]) or breast cancer–specific mortality (0.91 [0.81–1.03]) per additional year of cumulative use. CONCLUSIONS Our findings failed to show an association between improved survival and increased cumulative metformin duration in older breast cancer patients who had recent-onset diabetes. Further research is needed to clarify this association, accounting for effects of cancer stage and BMI in younger populations or those with differing stages of diabetes as well as in nondiabetic populations.

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference48 articles.

1. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis;Barone;JAMA,2008

2. Diabetes mellitus and breast cancer;Wolf;Lancet Oncol,2005

3. Breast cancer and diabetes mellitus;Schott;Exp Clin Endocrinol Diabetes,2010

4. Update on the Canadian Diabetes Association 2008 clinical practice guidelines;Bhattacharyya;Can Fam Physician,2009

5. Executive summary: Standards of medical care in diabetes—2012;American Diabetes Association;Diabetes Care,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3